| LIU, LIHong |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
| Completed | 2 | 3 | RoW | ICP-022 | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma | 11/21 | 12/21 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
| Not yet recruiting | 2 | 30 | RoW | R-EPOCH in Combination With Ibrutinib | Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd. | Richter Transformation | 08/24 | 08/25 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT05104775: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy |
|
|
| Recruiting | 1 | 58 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Hematologic Malignancies | 06/25 | 12/25 | | |
NCT04497688: Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 104 | RoW | PEG-rhG-CSF | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., Hebei Medical University Fourth Hospital | Non Hodgkin's Lymphoma | 09/20 | 10/20 | | |
NCT04678089: Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics |
|
|
| Enrolling by invitation | N/A | 350 | RoW | Bortezomib, PS-341, VELCADE | Beijing Chao Yang Hospital | Multiple Myeloma, Bortezomib | 12/22 | 12/23 | | |
NCT04665063: A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 20 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Hodgkin's Lymphoma | 10/23 | 10/25 | | |
NCT04665076: Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors |
|
|
| Recruiting | N/A | 60 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Plasma Cell Tumors | 10/23 | 10/25 | | |
NCT04666168: A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 200 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Non-hodgkin's Lymphoma | 10/23 | 10/25 | | |
RCG, NCT04660630: A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias |
|
|
| Active, not recruiting | N/A | 1172 | RoW | Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases, Drug gene chip, Regular follow-up and patient education | Beijing Chao Yang Hospital, China development research foundation | Hypertension,Essential, Diabetes type2, Hyperlipidemias | 12/23 | 01/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Liu, Yunjiang |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
NCT03580395: Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer |
|
|
| Enrolling by invitation | 2/3 | 200 | RoW | Apatinib, paclitaxel, cisplatin | Hebei Medical University Fourth Hospital | Breast Cancer | 07/22 | 12/22 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 350 | RoW | MRG002, Trastuzumab Emtansine for Injection | Shanghai Miracogen Inc. | Advanced Breast Cancer, Metastatic Breast Cancer | 09/23 | 10/23 | | |
NCT05004142: Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin |
|
|
| Recruiting | 2 | 70 | RoW | FCN-437c+Fulvestrant, FCN-437c+Letrozole+Goserelin | Ahon Pharmaceutical Co., Ltd., Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Affiliated Hospital of Hebei University | Breast Neoplasms | 12/21 | 06/23 | | |
NCT03728829: Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Trastuzumab+TP, Trastuzumab+Docetaxel+Carboplatin | Hebei Medical University Fourth Hospital, OrigiMed | Observational, Prospective | 10/22 | 12/22 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
NCT05114915: A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1b | 144 | RoW | Albumin-bound docetaxel | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 10/23 | 10/23 | | |
| Active, not recruiting | 1 | 297 | RoW | FS-1502 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Solid Tumor, Breast Cancer | 04/24 | 06/25 | | |
